Evaluación positiva de medicamentos: septiembre/octubre/noviembre 2014 Sanid. mil. 2015; 71 (1) 43 21. Duavive®, ficha técnica de la Agencia Europea de Medicamentos. Disponible en: http://ec.europa.eu/health/documents/communityregister/ 2014/20141216130229/anx_130229_es.pdf 22. Lobo RA., Pinkerton JV., Gass ML. , Dorin MH. , Ronkin S. , Pickar JH. et al: «Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.» Fertil Steril. 2009;92(3):1025–1038. Disponible en: http://www.ncbi. nlm.nih.gov/pubmed/19635615 23. Agencia Española de Medicamentos y Productos Sanitarios. Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios Septiembre 2014. Disponible en: http://www.aemps.gob.es/informa/boletinMensual/2014/ septiembre/docs/boletin-mensual_septiembre-2014.pdf 24. Committee for Medicinal Products for Human Use (CHMP). Ketoconazol. Disponible en:http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_ events/news/2014/09/news_detail_002174.jsp&mid=WC0b01ac058004d5c1 25. Committee for Medicinal Products for Human Use (CHMP). Moventig. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_ of_opinion_-_Initial_authorisation/human/002810/WC500173691.pdf 26. Chey WD., Webster L., Sostek M., Lappalainen .J, Barker PN., Tack J. et al: «Naloxegol for opioid-induced constipation in patients with noncancer pain. «N Engl J Med. 2014; 370(25):2387-2396. Disponible en: http://www.ncbi.nlm. nih.gov/pubmed/24896818 27. VARGATEF .FICHA TÉCNICA. Disponible en: http://www.ema.europa.eu/ docs/es_ES/document_library/EPAR_-_Product_Information/human/002569/ WC500179970.pdf 28. Committee for Merdicinal Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion__ Initial_authorisation/human/002569/WC500173607.pdf 29. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. Disponible en : http://www.nejm.org/doi/full/10.1056/NEJMoa1402584 30. Committe for Medicinal Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion__ Initial_authorisation/human/003821/WC500177632.pdf 31. Windyga J., Lissitchkov T., Stasyshyn O., Mamonov V., Rusen L., Lamas JL. et al: «Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.» Haemophilia. 2014; 20(1):15-24. Disponible en: http:// www.ncbi.nlm.nih.gov/pubmed/?term=NONACOG+GAMMA 32. Rixubis, ficha técnica de la Administración de Alimentos y Medicamentos de EE.UU Disponible en: http://www.baxter.com/downloads/healthcare_professionals/ products/RIXUBIS_PI.pdf 33. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G. et al: «Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.» Lancet Oncol. 2014;15(8):852- 861. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24882434 34. Lynparza. FDA Briefing Document. Oncologic Drugs Advisory Committee Meeting, June 25, 2014. Disponible en: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ UCM402207.pdf 35. Resumen opinión del EMA/CHMP/688255/2014 de 20 de noviembre de 2014. Disponible en: http: http://www.ema.europa.eu/docs/en_GB/document_ library/Summary_of_opinion_-_Initial_authorisation/human/003839/ WC500177626.pdf 36. Wurz GT, Kao CJ, DeGregorio MW. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Interv Aging. 2014 Nov 13;9:1939-50. doi: 10.2147/ CIA.S73753. eCollection 2014.Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/25419123 37. Committe for Medicinal Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion__ Initial_authorisation/human/002780/WC500177633.pdf 38. Fuchs CS., Tomasek J., Yong CJ., Dumitru F., Passalacqua R., Goswami C. et al: «Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.» Lancet. 2014; 383(9911):31-39. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term= RAMUCIRUMAB+gastric 39. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K et al ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1314258 40. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 41(12):1039–1046. December 2014 Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/1346-8138.12668/full 41. Committe for Medicinal Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_ opinion_-_Ini tial_authorisation/human/003729/WC500177620.pdf 42. Harvoni®, Ficha Técnica de la Agencia Europea de Medicamentos. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/ EPAR_-_Product_Information/human/003850/WC500177995.pdf 43. Afdhal N., Zeuzem S., Kwo .P, Chojkier M., Gitlin N., Puoti M. et al: «Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.» N Engl J Med. 2014; 370(20):1889-1898 Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/24725239 44. Afdhal N., Zeuzem S., Kwo .P, Chojkier M., Gitlin N., Puoti M. et al: «Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.» N Engl J Med. 2014; 370(16):1483-1493. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/24725238 45. Lymphoseek, Ficha Técnica de la Agencia Europea de Medicamentos. Disponible en: http://ec.europa.eu/health/documents/communityregister/ 2014/20141119129982/anx_129982_es.pdf 46. Wallace AM., Han LK., Povoski SP., Deck K., Schneebaum S., Hall NC. et al: «Comparative evaluation of (99m)tctilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.» Ann Surg Oncol. 2013;20(8):2590-2599. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/23504141 47. Marcinow AM., Hall N. , Byrum E., Teknos TN., Old MO., Agrawal A. et al: «Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study.» JAMA Otolaryngol Head Neck Surg. 2013;139(9):895-902. Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/24051744 48. Resumen opinión del EMA/CHMP/666694/2014 de 20 de noviembre de 2014. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/ Summary_of_opinion_-_Initial_authorisation/human/002814/WC500177579. pdf 49. Tricoci P, Huang Z, Held C, Moliterno D, Armstrong P, Van de Werf F, et al. Thrombin-receptor antagonist Vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33. 50. Morrow D, Braunwald E, Bonaca M, Ameriso S, Dalby A, Polly M, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366:1404-1413.
REVISTA DE SANIDAD FAS ENEMAR15
To see the actual publication please follow the link above